1. Home
  2. Analysis
  3. Ogen
  4. Femhrt

Ogen and Femhrt drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ogen (estropipate) and Femhrt (ethinyl estradiol; norethindrone acetate). Common drug interactions include breast cancer among females and breast cancer among males.

The phase IV clinical study analyzes what interactions people have when they take Ogen and Femhrt. It is created by eHealthMe based on reports of 83 people who take the same drugs from the FDA, and is updated regularly.

What is Ogen?

Ogen has active ingredients of estropipate. eHealthMe is studying from 2,553 Ogen users. Check the latest studies of Ogen.

What is Femhrt?

Femhrt has active ingredients of ethinyl estradiol; norethindrone acetate. It is often used in menopause. eHealthMe is studying from 2,025 Femhrt users. Check the latest studies of Femhrt.

On Jul, 27, 2026

83 people who take Ogen and Femhrt together, and have interactions are studied.

Ogen and Femhrt drug interactions.

What are the common drug interactions of Ogen and Femhrt, by gender? *:

female:

  1. Breast cancer
  2. Psychiatric symptom
  3. Deformity (disfigurement)
  4. Breast cancer metastatic
  5. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  6. Marital problem
  7. Fatigue (feeling of tiredness)
  8. Injury
  9. Neoplasm malignant (cancer tumour)
  10. Angiopathy (generic term for a disease of the blood vessels)

male:

  1. Breast cancer

What are the common drug interactions of Ogen and Femhrt, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Breast cancer metastatic
  2. Breast disorder
  3. Anxiety
  4. Breast cancer
  5. Breast cancer female
  6. Malignant neoplasm progression (cancer tumour came back)
  7. Oestrogen receptor assay positive
  8. Progesterone receptor assay positive
  9. Psychiatric symptom

50-59:

  1. Breast cancer
  2. Contralateral breast cancer (cancer of breast opposite side)
  3. Uterine cancer
  4. Breast cancer female
  5. Breast disorder
  6. Arthralgia (joint pain)
  7. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  8. Cheilitis (infection of lips)
  9. Cholecystitis chronic (long lasting infection of gallbladder)
  10. Crohn's disease (a condition that causes inflammation of the gastrointestinal tract)

60+:

  1. Breast cancer
  2. Anxiety
  3. Arthropathy
  4. Bereavement reaction
  5. Blood cholesterol increased
  6. Blood triglycerides increased
  7. Breast cancer in situ
  8. Breast cancer metastatic
  9. Cardiac disorder
  10. Cardiovascular disorder (heart diseases)

What are the existing conditions these people have? *

  1. Menopausal Symptoms: 11 people, 13.25%

* Approximation only. Some reports may have incomplete information.

Do you take Ogen and Femhrt?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Ogen and Femhrt:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ogen:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Femhrt:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ogen and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Femhrt and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on estropipate and ethinyl estradiol; norethindrone acetate (the active ingredients of Ogen and Femhrt, respectively), and Ogen and Femhrt (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.